Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

CNTX

CNTX News

Newswire

17:47

Context Therapeutics Advances CT-95 and CT-202 Programs with Promising Updates at Cancer Conference

07:33

Context Therapeutics presents CT-95 and CT-202 data at SITC Annual Meeting.

07:31

Context Therapeutics Highlights CT-95 and CT-202 Programs at SITC Annual Meeting

13:39

HC Wainwright Keeps Buy Rating on Context Therapeutics, Analysts Predict 366% Upside

08:35

Context Therapeutics: D. Boral Capital maintains Buy, PT raised to $9 from $8.

View More

About CNTX

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More